Alpha 2.0
Login Register
» Articles » PMID: 35333495

Patterns of Enrollment in Cancer Treatment Trials During the COVID-19 Pandemic at National Cancer Institute-Designated Cancer Centers

Overview
Journal Cancer J
Specialty Oncology
Date 2022 Mar 25
PMID 35333495
Authors
Sheila A Prindiville
Gisele A Sarosy
David Loose
Henry Ciolino
James H Doroshow
Affiliations
Soon will be listed here.
Abstract

The COVID-19 pandemic posed unprecedented strain on enrollment to cancer clinical trials and their conduct. Here, we highlight an analysis using information from the National Cancer Institute (NCI) Clinical Trials Reporting Program database to describe enrollment patterns to interventional cancer treatment trials at NCI-Designated Cancer Centers during the pandemic. Enrollment to cancer treatment trials at NCI-Designated Cancer Centers decreased precipitously early in the pandemic and has not yet fully returned to the 2019 baseline as of mid-2021. We discuss possible reasons for this and how some of the changes in clinical trial conduct implemented during the pandemic may become part of the standard conduct of NCI-supported clinical trials and broaden access to trials.

Citing Articles

Patient recruitment into clinical studies of solid malignancies during the COVID-19 pandemic in a tertiary cancer center.

von der Grun J, Ahmadsei M, Breyer I, Britschgi C, Eberli D, Hermanns T Neoplasia. 2024; 46:100946.

PMID: 39491410 PMC: 10630114. DOI: 10.1016/j.neo.2023.100946.

Patient Enrollment to Industry-Sponsored Versus Federally-Sponsored Cancer Clinical Trials.

Unger J, Xiao H, Vaidya R, LeBlanc M J Clin Oncol. 2024; 42(33):3917-3925.

PMID: 39331494 PMC: 11575909. DOI: 10.1200/JCO.24.00843.

Enrollment Success, Factors, and Prediction Models in Cancer Trials (2008-2019).

Zhang S, Zhang J, Liu S, Pang H, Stinchcombe T, Wang X JCO Oncol Pract. 2023; 19(11):1058-1068.

PMID: 37793091 PMC: 10667018. DOI: 10.1200/OP.23.00147.

Sponsor Perspectives on the Impact of the COVID-19 Pandemic on Interventional Cancer Clinical Trial Protocols and Data Quality.

Unger J, Stires H, Levit L, Stewart M, McKelvey B, Canin B JCO Oncol Pract. 2023; 19(10):907-916.

PMID: 37643386 PMC: 10615547. DOI: 10.1200/OP.23.00185.

Quantifying the impact of the COVID-19 pandemic on cancer center clinical trial operations.

George T, Lin T, Adrales Bentz T, Grant S, Houston C, Nashawati M JNCI Cancer Spectr. 2023; 7(4).

PMID: 37467065 PMC: 10463546. DOI: 10.1093/jncics/pkad048.

References
1.
Unger J, Xiao H, LeBlanc M, Hershman D, Blanke C . Cancer Clinical Trial Participation at the 1-Year Anniversary of the Outbreak of the COVID-19 Pandemic. JAMA Netw Open. 2021; 4(7):e2118433. PMC: 8323000. DOI: 10.1001/jamanetworkopen.2021.18433. View
2.
Gupta D, Kato S, Kurzrock R . The Impact of COVID-19 on Cancer Clinical Trials Conducted by NCI-Designated Comprehensive Cancer Centers. J Immunother Precis Oncol. 2021; 4(2):56-63. PMC: 8320380. DOI: 10.36401/jipo-20-30. View
3.
Fleury M, Farner A, Unger J . Association of the COVID-19 Outbreak With Patient Willingness to Enroll in Cancer Clinical Trials. JAMA Oncol. 2020; 7(1):131-132. PMC: 7662493. DOI: 10.1001/jamaoncol.2020.5748. View
4.
Flaherty K, Doroshow J, Galbraith S, Ribas A, Kluetz P, Pazdur R . Rethinking Cancer Clinical Trial Conduct Induced by COVID-19: An Academic Center, Industry, Government, and Regulatory Agency Perspective. Cancer Discov. 2021; 11(8):1881-1885. PMC: 8340848. DOI: 10.1158/2159-8290.CD-21-0850. View
5.
Yeboa D, Anakwenze Akinfenwa C, Nguyen J, Amaya D, de Gracia B, Ning M . Effectively Conducting Oncology Clinical Trials During the COVID-19 Pandemic. Adv Radiat Oncol. 2021; 6(3):100676. PMC: 7927592. DOI: 10.1016/j.adro.2021.100676. View